0001104659-23-112750.txt : 20231031 0001104659-23-112750.hdr.sgml : 20231031 20231031073517 ACCESSION NUMBER: 0001104659-23-112750 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231031 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231031 DATE AS OF CHANGE: 20231031 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd. CENTRAL INDEX KEY: 0001730430 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38492 FILM NUMBER: 231362304 BUSINESS ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 BUSINESS PHONE: 7814399100 MAIL ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 8-K 1 tm2329311-1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 31, 2023

Kiniksa Pharmaceuticals, Ltd.

(Exact name of Registrant as Specified in Its Charter)

Bermuda		001-730430		98-1327726
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

Kiniksa Pharmaceuticals, Ltd.

Clarendon House

2 Church Street

Hamilton HM11, Bermuda
(808) 451-3453

(Address, zip code and telephone number, including area code of principal executive offices)

Kiniksa Pharmaceuticals Corp.

100 Hayden Avenue

Lexington, MA, 02421

(781) 431-9100

(Address, zip code and telephone number, including area code of agent for service)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Shares $0.000273235 par value		KNSA		The Nasdaq Stock Market LLC
				(Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02. Results of Operations and Financial Condition.

On October 31, 2023, Kiniksa Pharmaceuticals, Ltd. issued a press release announcing financial results for the quarter ended September 30, 2023. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.

The information contained in this Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing and except as expressly provided by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description

99.1		Q3 Earnings Press Release issued by Kiniksa Pharmaceuticals, Ltd. dated October 31, 2023

104		Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	KINIKSA PHARMACEUTICALS, LTD.

Date: October 31, 2023	By:	/s/ Madelyn Zeylikman
		Madelyn Zeylikman
		Senior Vice President, General Counsel and Secretary

EX-99.1 2 tm2329311d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution

– ARCALYST^®(rilonacept) Q3 2023 net product revenue of $64.8 million, representing ~94% year-over-year growth –

– KPL-404 Phase 2 rheumatoid arthritis data from Cohorts 1-3 now expected in Q1 2024 –

– Cash reserves of $201 million expected to fund operations into at least 2027 –

– Conference call and webcast scheduled for 8:30 am ET today –

HAMILTON, BERMUDA – October 31, 2023 – Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported third quarter 2023 financial results and recent portfolio execution.

“We continue to advance all aspects of our business, including strong revenue growth with ARCALYST and clinical trial execution with KPL-404, and we have cash runway into at least 2027,” said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. “On the commercial side, we are building the recurrent pericarditis market and are focused on helping as many patients as possible. We are currently tracking to the high end of our previously issued guidance of $220 million to $230 million in product revenue. Within our clinical development portfolio, we have completed enrollment in the third cohort of the Phase 2 trial of KPL-404 in rheumatoid arthritis. We now expect data from Cohorts 1-3 in the first quarter of 2024.”

Portfolio Execution

ARCALYST (IL-1α and IL-1β cytokine trap)

·

ARCALYST net product revenue was $64.8 million for the third quarter of 2023.

·

Since launch, more than 1,450 prescribers have written ARCALYST prescriptions for recurrent pericarditis.

·

As of the end of the third quarter of 2023, average total duration of ARCALYST therapy in recurrent pericarditis was approximately 20 months.

-

Average total duration of therapy includes the approximately 45% of patients who restarted ARCALYST, within an average of 8 weeks, after having discontinued therapy.

1

KPL-404 (monoclonal antibody inhibitor of CD40-CD154 interaction)

·

Kiniksa completed enrollment of the third cohort of the Phase 2 clinical trial of KPL-404 in rheumatoid arthritis. The company now expects data from Cohorts 1-3 in the first quarter of 2024.

·

Kiniksa is currently enrolling a fourth cohort (Cohort 4) of the Phase 2 clinical trial of KPL-404 in rheumatoid arthritis. The additional cohort will evaluate a fixed dose level administered as a single subcutaneous injection once monthly. The company expects data from Cohort 4 in the second quarter of 2024.

Mavrilimumab (monoclonal antibody inhibitor targeting GM-CSFRα)

·

Kiniksa is pursuing collaborative study agreements to evaluate the potential of mavrilimumab in rare cardiovascular diseases where the granulocyte macrophage colony stimulating factor (GM-CSF) mechanism has been implicated.

Financial Results

·

ARCALYST net product revenue for the third quarter of 2023 was $64.8 million, compared to $33.4 million for the third quarter of 2022.

-

Total revenue for the third quarter of 2023 was $67.0 million, including $2.2 million in license and collaboration revenue, compared to total revenue for the third quarter of 2022 of $99.1 million, including $65.7 million in license and collaboration revenue.

·

Total operating expenses for the third quarter of 2023 were $78.0 million, compared to $52.7 million for the third quarter of 2022.

-

Total operating expenses for the third quarter of 2023 included $17.3 million in collaboration expenses, due to increasing ARCALYST profitability, compared to $4.6 million for the third quarter of 2022.

-

Total operating expenses for the third quarter of 2023 included $6.8 million in non-cash, share-based compensation expense, compared to $6.0 million for the third quarter of 2022.

·

Net loss for the third quarter of 2023 was $13.9 million, compared to net income of $224.1 million for the third quarter of 2022.

·

As of September 30, 2023, Kiniksa had $201.1 million of cash, cash equivalents, and short-term investments and no debt.

Financial Guidance

·

Kiniksa expects 2023 ARCALYST net product revenue of between $220 million and $230 million.

·

Kiniksa expects that its cash, cash equivalents, and short-term investments will fund its current operating plan into at least 2027.

2

Conference Call Information

·

Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, October 31, 2023, to discuss third quarter 2023 financial results and recent portfolio execution.

·

Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. To access the webcast, please visit the Investors and Media section of Kiniksa’s website. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa

Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST, KPL-404, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.

About ARCALYST

ARCALYST is a weekly, subcutaneously injected recombinant dimeric fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling. ARCALYST was discovered by Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the U.S. Food and Drug Administration (FDA) for recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome, and deficiency of IL-1 receptor antagonist (DIRA). The FDA granted Breakthrough Therapy designation to ARCALYST for the treatment of recurrent pericarditis in 2019 and Orphan Drug exclusivity to ARCALYST in 2021 for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and pediatric patients 12 years and older. The European Commission granted Orphan Drug Designation to ARCALYST for the treatment of idiopathic pericarditis in 2021.

IMPORTANT SAFETY INFORMATION ABOUT ARCALYST

·

ARCALYST may affect your immune system and can lower the ability of your immune system to fight infections. Serious infections, including life-threatening infections and death, have happened in patients taking ARCALYST. If you have any signs of an infection, call your doctor right away. Treatment with ARCALYST should be stopped if you get a serious infection. You should not begin treatment with ARCALYST if you have an infection or have infections that keep coming back (chronic infection).

·

While taking ARCALYST, do not take other medicines that block interleukin-1, such as Kineret^®(anakinra), or medicines that block tumor necrosis factor, such as Enbrel^®(etanercept), Humira^® (adalimumab), or Remicade^® (infliximab), as this may increase your risk of getting a serious infection.

·

Talk with your doctor about your vaccine history. Ask your doctor whether you should receive any vaccines before you begin treatment with ARCALYST.

·

Medicines that affect the immune system may increase the risk of getting cancer.

3

·

Stop taking ARCALYST and call your doctor or get emergency care right away if you have any symptoms of an allergic reaction.

·

Your doctor will do blood tests to check for changes in your blood cholesterol and triglycerides.

·

Common side effects include injection-site reactions (which may include pain, redness, swelling, itching, bruising, lumps, inflammation, skin rash, blisters, warmth, and bleeding at the injection site), upper respiratory tract infections, joint and muscle aches, rash, ear infection, sore throat, and runny nose.

For more information about ARCALYST, talk to your doctor and see the Product Information.

About KPL-404

KPL-404 is an investigational humanized monoclonal antibody that is designed to inhibit CD40-CD154 (CD40 ligand) interaction, a key T-cell co-stimulatory signal critical for B-cell maturation and immunoglobulin class switching and Type 1 immune responses. Kiniksa believes disrupting the CD40-CD154 interaction is an attractive approach to address multiple autoimmune disease pathologies.

About Mavrilimumab

Mavrilimumab is an investigational fully human monoclonal antibody that blocks activity of GM-CSF by specifically binding to the alpha subunit of the GM-CSF receptor (GM-CSFRα). Phase 2 clinical trials of mavrilimumab in rheumatoid arthritis and giant cell arteritis achieved their primary and secondary endpoints with statistical significance. Kiniksa is evaluating the development of mavrilimumab in rare cardiovascular diseases where the GM-CSF mechanism has been implicated.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding: our expectation that we will report data from cohorts 1-3 of our Phase 2 clinical trial of KPL-404 in rheumatoid arthritis in the first quarter of 2024 and data from cohort 4 of such trial in the second quarter of 2024; our expectation that our full-year net product revenue will be at the high end of our $220 million to $230 million guidance range; our expectation about our cash reserves funding our current operating plan into at least 2027; our beliefs about the mechanisms of action of our product candidates and potential impact of their approach, including that using KPL-404 to disrupt the CD40-CD154 interaction is an attractive approach to address multiple autoimmune disease pathologies; and our belief that all of our product candidates offer the potential for differentiation.

4

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including without limitation, the following: delays or difficulty in enrollment of patients in, and activation or continuation of sites for, our clinical trials; delays or difficulty in completing our clinical trials as originally designed; potential for changes between final data and any preliminary, interim, top-line or other data from clinical trials; our inability to replicate results from our earlier clinical trials or studies; impact of additional data from us or other companies, including the potential for our data to produce negative, inconclusive or commercially uncompetitive results; potential undesirable side effects caused by our products and product candidates; our inability to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities; potential for applicable regulatory authorities to not accept our filings, delay or deny approval of any of our product candidates or require additional data or trials to support approval; inability to successfully execute on our commercial strategy for ARCALYST; our reliance on third parties as the sole source of supply of the drug substance and drug product used in our products and product candidates; our reliance on Regeneron as the current sole manufacturer of ARCALYST; risks arising from our ongoing technology transfer of ARCALYST drug substance manufacturing; raw material, important ancillary product and drug substance and/or drug product shortages; our reliance on third parties to conduct research, clinical trials, and/or certain regulatory activities for our product candidates; complications in coordinating requirements, regulations and guidelines of regulatory authorities across jurisdictions for our clinical trials; changes in our operating plan, business development strategy or funding requirements; and existing or new competition.

These and other important factors discussed in our filings with the U.S. Securities and Exchange Commission, including under the caption “Risk Factors” contained therein, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. Except as required by law, we disclaim any intention or obligation to update or revise any forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

ARCALYST^® is a registered trademark of Regeneron. All other trademarks are the property of their respective owners.

Every Second Counts! ^®

Kiniksa Investor and Media Contact

Rachel Frank

(339) 970-9437

rfrank@kiniksa.com

5

KINIKSA PHARMACEUTICALS, LTD.

SELECTED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(In thousands)

(Unaudited)

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2023				2022				2023				2022
Revenue:
Product revenue, net		$	64,802			$	33,424			$	161,956			$	82,585
License and collaboration revenue			2,244				65,711				24,908				75,711
Total revenue			67,046				99,135				186,864				158,296
Costs and operating expenses:
Cost of goods sold			9,088				6,937				23,823				16,185
Collaboration expenses			17,311				4,623				39,585				16,549
Research and development			17,106				16,485				56,045				51,100
Selling, general and administrative			34,468				24,677				92,688				70,736
Total operating expenses			77,973				52,722				212,141				154,570
Income (loss) from operations			(10,927	)			46,413				(25,277	)			3,726
Other income			2,428				322				6,175				459
Income (loss) before income taxes			(8,499	)			46,735				(19,102	)			4,185
Benefit (provision) for income taxes			(5,356	)			177,358				7,949				174,717
Net income (loss)		$	(13,855	)		$	224,093			$	(11,153	)		$	178,902
Net income (loss) per share attributable to common shareholders—basic		$	(0.20	)		$	3.23			$	(0.16	)		$	2.58
Net income (loss) per share attributable to common shareholders—diluted		$	(0.20	)		$	3.18			$	(0.16	)		$	2.55
Weighted average common shares outstanding—basic			70,186,016				69,445,071				69,953,591				69,305,755
Weighted average common shares outstanding—diluted			70,186,016				70,552,018				69,953,591				70,286,444

KINIKSA PHARMACEUTICALS, LTD.

SELECTED CONSOLIDATED BALANCE SHEET DATA

(In thousands)

(Unaudited)

		As of
		September 30,				December 31,
		2023				2022
Cash, cash equivalents, and short-term investments		$	201,084			$	190,608
Working capital			202,641				195,994
Total assets			483,063				459,672
Accumulated deficit			(503,187	)			(492,034	)
Total shareholders' equity			405,127				396,149

6

EX-101.SCH 3 knsa-20231031.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 knsa-20231031_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 knsa-20231031_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2329311d1_ex99-1img001.jpg GRAPHIC begin 644 tm2329311d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Oct. 31, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Oct. 31, 2023
Entity File Number	001-730430
Entity Registrant Name	Kiniksa Pharmaceuticals, Ltd.
Entity Central Index Key	0001730430
Entity Tax Identification Number	98-1327726
Entity Incorporation, State or Country Code	D0
Entity Address, Address Line One	Clarendon House
Entity Address, Address Line Two	2 Church Street
Entity Address, City or Town	Hamilton
Entity Address, Country	BM
Entity Address, Postal Zip Code	HM11
City Area Code	808
Local Phone Number	451-3453
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Class A Common Shares $0.000273235 par value
Trading Symbol	KNSA
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 8 tm2329311-1_8k_htm.xml IDEA: XBRL DOCUMENT 0001730430 2023-10-31 2023-10-31 iso4217:USD shares iso4217:USD shares 0001730430 false 8-K 2023-10-31 Kiniksa Pharmaceuticals, Ltd. D0 001-730430 98-1327726 Clarendon House 2 Church Street Hamilton HM11 BM 808 451-3453 false false false false Class A Common Shares $0.000273235 par value KNSA NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / " 6P0 M !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " !H/%]7)!Z;HJT #X 0 M&@ @ ',$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0 M2P$"% ,4 " !H/%]799!YDAD! #/ P $P @ &Q$@ I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #[$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://kiniksa.com/role/Cover Cover Cover 1 false false All Reports Book All Reports knsa-20231031.xsd knsa-20231031_lab.xml knsa-20231031_pre.xml tm2329311-1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2329311-1_8k.htm": { "nsprefix": "knsa", "nsuri": "http://kiniksa.com/20231031", "dts": { "schema": { "local": [ "knsa-20231031.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "knsa-20231031_lab.xml" ] }, "presentationLink": { "local": [ "knsa-20231031_pre.xml" ] }, "inline": { "local": [ "tm2329311-1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://kiniksa.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-10-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2329311-1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2329311-1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://kiniksa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-23-112750-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-112750-xbrl.zip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end